Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medium-dose versus high-dose CoronaVac booster immunogenicity study
ChiCTR2100052697Phase 4Recruiting
- Sponsor
- Beijing YouAn Hospital
- Start
- Oct 2021
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of coronavac in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Beijing YouAn Hospital. Primary endpoint: Serum neutralizing antibody. Started Oct 2021; status: recruiting.
02
Drugs
coronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2100052697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052697.